RxDoctor Payments Data

Robert Parkes, MD

Interventional Cardiology · Schenectady, NYNPI 1235189663

Payments from drug & device makers

$3,576in general payments, 2019–2025

Across 183 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$494
  • Abbott$321
  • Boston Scientific$306
  • Boehringer Ingelheim$283
  • Abiomed$260
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$253
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$3,569100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,576 in reported general payments places this provider in the 25th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$89,514
Medicare patients
677
Services billed
1,352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban276$309,759
XareltoRivaroxaban48$57,648
Repatha SureclickEvolocumab35$39,474
EntrestoSacubitril/Valsartan19$26,354
JardianceEmpagliflozin11$19,250
BrilintaTicagrelor19$15,903
Praluent PenAlirocumab25$11,894
Metoprolol Succinate406$5,460
Atorvastatin Calcium424$5,265
Valsartan81$2,927
Rosuvastatin Calcium116$2,188
Eplerenone16$2,119
ClopidogrelClopidogrel Bisulfate198$1,917
Amlodipine Besylate239$1,853
Losartan Potassium121$1,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$309,759276 claims
Johnson & JohnsonXarelto$183$57,64848 claims
NovartisEntresto$494$26,35419 claims
Boehringer IngelheimJardiance$283$19,25011 claims
AstraZenecaBrilinta$161$15,90319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Schenectady

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →